Financial Performance - Q1 2025 revenue reached $239.1 million[12] - Q1 2025 unlevered free cash flow was $86.8 million[12] - Q1 2025 non-GAAP gross margin was 82%[12] - Q1 2025 recurring revenue was 96%[12] - The company forecasts revenue between $970 million and $980 million for the full year 2025[52] - The company forecasts unlevered free cash flow between $265 million and $275 million for the full year 2025[52] Market Position and Growth - The company is a category leader in Exposure Management[11] - The company has approximately 44,000 customers[12] - The company is ranked 1 in market share in Vulnerability Management[12, 23] - The total addressable market for cyber exposure is estimated at $33 billion with an 18% CAGR[29]

Company Strategy and Focus - SandRidge Energy's primary strategic focus is to grow the cash value and generation capability of its asset base to accelerate shareholder value realization in a safe, responsible, and efficient manner[7] - The company aims to extend and flatten its production profile with low capital, high return projects and well reactivations[7] - The company is focused on lower risk, PDP-weighted assets that fit its core cost efficiency and production optimization competencies for opportunistic acquisitions[7] Asset Base and Production - The company has a long-lived Midcon asset position with a more than 9 year average reserve life[11] - The company's Q1 2021 net production was 175 thousand barrels of oil equivalent per day (Mboe/d), with approximately 47% liquids[12] - The company's PD reserves are 602 million barrels of oil equivalent (MMBoe) with a PV-10 value of approximately $233 million[12] Financial Performance and Cost Reduction - The company has lowered its absolute LOE by more than 70% and its LOE per Boe by more than 40% since 2016[22] - The company has lowered its absolute and per Boe G&A by more than 60% since 2018[43] - The company achieved 1Q21 Gas and NGL realizations 52% and 79% higher, respectively, than their LTM averages[27] Safety and ESG Commitment - The company is approaching three years without a Total Recordable Incident Rate (TRIR), currently at 33 months[18] - The company has a disciplined ESG commitment with a focus on environmental, social, and governance aspects[5]

Financial Performance & Guidance - Cerus is raising its full-year 2024 product revenue guidance to $177 - $179 million, anticipating a 12-14% increase compared to full-year 2023 product revenue[13] - The bottom end of the 2024 IFC guidance range has been raised to $9 - $10 million, from the prior $8 - $10 million[13] - In Q3 2024, Non-GAAP Adjusted EBITDA reached $4.4 million[32] Product & Market - The global addressable market for INTERCEPT products is estimated at $1.3 billion, with potential growth to over $1.5 billion in 5-7 years[22] - The U S addressable market is $150 million, with potential growth to over $200 million in 5-7 years[22] - Cerus' preliminary 2023 product revenue was $156 million[22] Strategic Initiatives - Cerus has a new BARDA contract for INTERCEPT RBCs[11] - The company submitted a CE Mark for its LED Illuminator[11] - Cerus is focused on adjusted EBITDA and operating cash flow goals[25]

Financial Performance & Outlook - Cerus achieved positive non-GAAP adjusted EBITDA for Q4 and full year 2024 [9] - The company anticipates product revenue growth of 8% to 11% year-over-year in 2025 [9] - Cerus is committed to sustaining positive adjusted EBITDA for fiscal year 2025 [9] - GAAP net loss attributable to Cerus improved by over 40% in 2024 compared to 2023 [9] - In 2024, Cerus achieved 15% topline growth due to strong team performance and blood center partnerships [10] Market & Product Expansion - Cerus is focused on the continued global expansion of its platelet franchise [9] - The company expects increasing uptake of INTERCEPT Fibrinogen Complex (IFC) in the US [9] - The global addressable market for INTERCEPT products is currently $1.3 billion and is expected to grow to over $1.5 billion in the next 5-7 years [16] - The U S addressable market is $150 million and is expected to grow to over $200 million in the next 5-7 years [16] Technology & Impact - Cumulative kit sales for over 16 million INTERCEPT treated doses of platelets & plasma [5]

Clinical Trial Results - Bivamelagon achieved statistically significant BMI reductions in patients with acquired hypothalamic obesity at 14 weeks[5] - At 14 weeks, the 200mg Bivamelagon group saw a mean BMI reduction of 268%, the 400mg group saw a mean BMI reduction of 769%, and the 600mg group saw a mean BMI reduction of 931%[27] - In the placebo group, there was a mean BMI increase of 218% from baseline at 14 weeks[27] - A significant percentage of patients achieved clinically meaningful BMI reductions: 167% in the 200mg Bivamelagon group, 714% in the 400mg group, and 75% in the 600mg group achieved at least a 5% BMI reduction[33] - Bivamelagon also achieved meaningful reductions in 'most' hunger scores at Week 14[44] Safety and Tolerability - Safety and tolerability results were generally consistent with an MC4R MOA and setmelanotide trials in acquired hypothalamic obesity, with limited instances of localized hyperpigmentation[5] - The most common AEs with >=10% in all BIVA dosing (N=21) were nausea, diarrhea, vomiting, and headache[47] Market Opportunity and Future Development - Rhythm Pharmaceuticals intends to request an End-of-Phase 2 meeting with the FDA with intentions to move forward to Phase 3[5] - The company estimates the U S prevalence of acquired hypothalamic obesity to be 5,000 – 10,000 patients[13] - U S patent protection for bivamelagon and RM-718 extends into the 2040s[13]

Acquisition Overview - Merck将以每ADS 107美元的价格收购Verona Pharma的所有已发行股份[14,47]，总交易价值约为100亿美元[14,47]（约98亿美元扣除约2亿美元的现金、投资和债务[47]），预计将于2025年第四季度完成[14,47] - 这项以科学为驱动的业务发展[14]，加强并补充了心肺产品组合[14] - Ohtuvayre®是20多年来的首个新型吸入性COPD维持治疗药物[14]，这是一个巨大的疾病领域，存在着显著未被满足的医疗需求[14] Ohtuvayre® Clinical Data - Ohtuvayre®是一种磷酸二酯酶3（PDE3）和磷酸二酯酶4（PDE4）的双重抑制剂[24]，是20多年来首个用于COPD维持治疗的新型吸入机制[24] - 在两项3期试验中，Ohtuvayre®在肺功能方面表现出具有临床意义的改善，平均FEV1 AUC0-12h从基线相比安慰剂显著改善+87 mL和+94 mL[25,27] - 汇总数据显示，在ENHANCE-1和ENHANCE-2研究中，Ohtuvayre®降低了24周内的年度中度或重度加重率[28,29]，ENHANCE-2研究中，Ensifentrine 3 mg组的年度事件率为0.24，安慰剂组为0.42[29]，风险比为0.57[29]，降低了43%[29] Commercial Opportunity - 美国约有860万接受维持治疗的COPD患者[35,40]，其中约50%仍然持续有症状[36,40]，针对持续有症状的患者是启动重点[40]，人数约为430万[40] - 2025年第一季度，处方量约为25000张[42]，约60%的处方是续方[42]，自上市以来约有5300名处方医生[42]，相比2024年第四季度，处方医生增加了约50%[42] - Ohtuvayre®代表着到2030年代中期的一个数十亿美元的商业机会[14,43] Financial Impact - 预计该交易将在最初的12个月内对非GAAP每股收益产生约0.16美元的负面影响[47]，这代表着与为交易融资相关的成本，部分被Ohtuvayre®的业绩所抵消[47]，预计将在2027年实现非GAAP每股收益的增厚[47]，并在2028年全年实现增厚[47]

Financial Performance & Growth - FY21 sales reached over $1.3 billion, with a 20.7% sales growth[14] - FY21 Adjusted EBITDA was $271 million, reflecting a 48.0% growth[14] - First half of Fiscal Year 2022 (1H22) sales were $413 million, a 22% increase[26] - 1H22 Adjusted EBITDA grew by 5.5% to $10 million, with an Adjusted EBITDA margin of 2.4%[26] - The company revised its Fiscal Year 2022 sales guidance to $1.575 billion - $1.610 billion, representing a 17%-20% growth[30] - Revised Fiscal Year 2022 Adjusted EBITDA guidance is $315 million - $330 million, a 16%-22% increase[30] Strategic Initiatives & Market Position - The U.S pool & spa aftermarket opportunity is estimated at $14 billion[21] - The company operates 970 locations across 39 states[23, 29] - Digital properties capture 60% of specialty direct-to-consumer pool traffic[23] - The PRO business grew by 27% in 1H22 and accounts for approximately 15% of Last Twelve Months (LTM) total sales[29]

Company Overview - Leslie's is the largest direct-to-consumer brand in the pool and spa care industry, with fiscal year 2021 sales exceeding $1.3 billion, representing a 20.7% sales growth[14] - The company's adjusted EBITDA for fiscal year 2021 was $271 million, a 48% increase[14] - Leslie's operates 970 locations across 39 states[24] Market Opportunity - The U S pool and spa aftermarket opportunity is estimated at $14 billion[22, 35] - The addressable market includes 8.7 million residential pools representing a $7.6 billion total addressable market (TAM)[31] - There are 5.5 million addressable spas representing a $2 billion TAM[33] - The professional pool market includes 250,000 commercial pools and 45,000 pool professionals, representing a $4.3 billion TAM[35] Growth & Financial Performance - First half of fiscal year 2022 sales reached $413 million, a 22% increase[82] - The company's first half of fiscal year 2022 adjusted EBITDA grew by 5.5% to $10 million[82] - The PRO business grew by 27% in the first half of fiscal year 2022 and represents approximately 15% of last twelve months (LTM) total sales[85] Fiscal Year 2022 Guidance - Revised fiscal year 2022 sales guidance is between $1.575 billion and $1.61 billion, representing a 17%-20% growth[89] - Revised fiscal year 2022 adjusted EBITDA is projected to be between $315 million and $330 million, a 16%-22% increase[89]

Financial Performance - Net sales decreased by 4.7% to $685.1 million compared to $718.6 million in Q1 2013 [12] - Reported EPS decreased by 14% to $0.69, primarily due to a Venezuela remeasurement loss [4] - Adjusted EPS decreased by 1% to $0.91 [4] - Reported operating income margin was 11.7%, down 60 basis points, while adjusted operating income margin was 14.3%, up 50 basis points [4] - The company returned $70 million in cash to shareholders through share repurchases and dividends [4] Sales Volume and Market Trends - Sales volume decreased by 5.0% [4] - Q1-2014 volume trends improved in March, but March and April volume run-rates remain below prior year levels [6] - Net Sales in North America decreased by 4.2% to $401.9 million [14] - Net Sales in Europe decreased by 4.6% to $105.4 million [16] - Net Sales in Asia Pacific decreased by 12.5% to $61.3 million [18] - Net Sales in Venezuela increased by 20.9% to $44.0 million [20] - Net Sales in The Harris Products Group decreased by 11.7% to $72.5 million [23] Capital Allocation - Dividends paid in Q1 2014 totaled $19 million, a 15% increase to $0.23 per common share [27] - Share repurchases in Q1 2014 increased by 299% to $51 million [28] - Capital expenditures in Q1 2014 decreased by 4% to $15 million [28]

Financial Performance - Net sales remained steady, increasing by 0.2% to $728.5 million[11], but excluding foreign exchange, sales increased by 2%[4] - Reported operating income margin increased by 110 basis points to 15.4%, with a record Q2 adjusted operating income margin of 16.0%, up 120 basis points[4] - Reported EPS increased by 10% to $0.96, while adjusted EPS increased by 11% to $1.01[4] - Cash returned to shareholders increased by 18% to $87 million through share repurchases and dividends[4] Segment Performance - North America net sales increased by 2.5% to $429.5 million, with adjusted EBIT increasing by 10.2% to $91.2 million[13] - Europe net sales increased by 6.4% to $115.6 million, with adjusted EBIT increasing significantly by 56.3% to $14.9 million[15] - Asia Pacific net sales decreased by 3.2% to $67.0 million, with adjusted EBIT decreasing by 44.1% to $0.4 million[17] - South America net sales decreased by 12.3% to $39.1 million, with adjusted EBIT decreasing by 54.9% to $5.0 million, impacted by the Venezuelan operation[19] - Harris net sales decreased by 9.9% to $77.4 million, with adjusted EBIT decreasing by 2.2% to $7.2 million[25] Venezuela Impact - Q2 2014 results include $19.0 million in net sales and $4.4 million in adjusted EBIT from the Venezuelan operation[12, 20] - A $3.5 million charge was taken to cost of goods sold in Q2 2014 related to currency remeasurement to SICAD I[20, 24]